Since its first approval by the Food and Drug Administration in 1989 for strabismus,
botulinum toxin indications of use have been widely expanded. Due to its anticholinergic …

Botulinum toxin type-A (BoNT-A) has emerged as a key therapeutic agent for the
management of spasticity. This paper presents a comprehensive bibliometric and visual …

PURPOSE: The open-label phase 3 “Treatment with IncobotulinumtoxinA in Movement
Open-Label”(TIMO) study investigated longer-term safety and efficacy of …

Background: The occurrence of sialorrhea (drooling) in children with cerebral palsy is one of
the important complications of this disease, which is associated with the impaired quality of …

Botulinum neurotoxins are a group of biological toxins produced by the gram-negative
bacteria Clostridium botulinum. After intramuscular injection, they produce dose-related …

PURPOSE: A large prospective database from three Phase 3 studies allowed the study of
spasticity-related pain (SRP) in pediatric cerebral palsy (CP). METHODS: Baseline …

IncobotulinumtoxinA, a pure botulinumtoxinA formulation, is free of accessory proteins. This
analysis provides pooled safety data from phase 3 trials of children/adolescents (2–17 …

Objective Evaluate safety and effectiveness of thermal radiofrequency in the
musculocutaneous nerve in patients with focal elbow flexor spasticity. Design Ambispective …

There is no gold-standard treatment for idiopathic toe walking (ITW). Some previous
evidence suggested that botulinum neurotoxin-A injection might improve ITW. This is a …

PURPOSE: This pooled analysis of data from three Phase 3 studies investigated the effects
of incobotulinumtoxinA on spasticity-related pain (SRP) in children/adolescents with uni …